Skip to Content

A Blood Test for Alzheimer’s?

Biomarkers could help target preventative treatments.
October 15, 2007

Scientists at Stanford University have identified a set of protein biomarkers in the blood that can correctly identify people with Alzheimer’s and predict which patients with mild cognitive impairment will go on to develop the disease. If replicated in larger studies, this protein profile could drastically improve on existing methods to diagnose the disease. Because cognitive symptoms don’t usually appear until the brain has undergone significant damage, and no reliable physical symptoms have yet been identified, accurate diagnosis relies largely on cognitive testing and lab tests to rule out other problems. The study was published Monday in the journal Nature Medicine.

The test is being commercialized by Satoris, based in San Francisco. In a press release issued by the company, Tony Wyss-Coray, a neurologist at Stanford University School of Medicine and company cofounder, said,

“Our data indicate blood contains a highly specific, bio­logical signature that can characterize Alzheimer’s disease years before a clinical diagnosis can be made.”

The blood test could also aid in the development of new treatments to stop the progression of the disease and help target those treatments to those who need them. Alzheimer’s disease is usually preceded by a period of milder impairment, known as mild cognitive dysfunction. But not everyone with mild cognitive impairment will go on to develop Alzheimer’s, making it difficult to test new drugs designed to stop the progression. Pharmaceutical companies are actively searching for biomarkers that predict the disease. (See “Tackling a $100 Billion Disease.”)

Keep Reading

Most Popular

10 Breakthrough Technologies 2024

Every year, we look for promising technologies poised to have a real impact on the world. Here are the advances that we think matter most right now.

Scientists are finding signals of long covid in blood. They could lead to new treatments.

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.

AI for everything: 10 Breakthrough Technologies 2024

Generative AI tools like ChatGPT reached mass adoption in record time, and reset the course of an entire industry.

What’s next for AI in 2024

Our writers look at the four hot trends to watch out for this year

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.